2 results  1 of 1 

1 The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A
Ju Young Kim, Chur Woo You
Blood Res.2019;54(3):204-209.   Published online 2019 September 25     DOI: http://dx.doi.org/10.5045/br.2019.54.3.204
      
2 Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study
Soon Ki Kim, Ki Young Yoo, Kun Soo Lee, Taiju Hwang, Yong Mook Choi, Eun Jin Choi, Sang Kyu Park
J Korean Med Sci.2018;33(1):e5.  Published online 2017 November 10     DOI: http://dx.doi.org/10.3346/jkms.2018.33.e5
      

 1 of 1